Effect of diet and omega-3 fatty acid intervention on asymmetric dimethylarginine

1743-7075-3-4 1743-7075 Research Effect of diet and omega-3 fatty acid intervention on asymmetric dimethylarginine Eid MA Hilde h.m.eid@medisin.uio.no Arnesen Harald harald.arnesen@uus.no Hjerkinn M Elsa elsa.hjerkinn@uus.no Lyberg Torstein torstein.lyberg@uus.no Ellingsen Ingrid ingrid.ellingsen@uus.no Seljeflot Ingebjørg ingebjorg.seljeflot@uus.no

Center for Clinical Research, Ullevaal University Hospital, Oslo, Norway

Department of Cardiology, Ullevaal University Hospital, Oslo, Norway

Department of Preventive Cardiology, Ullevaal University Hospital, Oslo, Norway

Nutrition & Metabolism 1743-7075 2006 3 1 4 http://www.nutritionandmetabolism.com/content/3/1/4 16396682 10.1186/1743-7075-3-4 30 8 2005 05 1 2006 05 1 2006 2006 Eid et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background and aim

Impaired vasodilatation has been suggested to be caused by inhibition of nitric oxide generation by the recently described asymmetric dimethylarginine (ADMA). In the present study we wanted to explore whether n-3 polyunsaturated fatty acid (PUFA) supplementation and/or diet intervention have beneficial influence on endothelial function assessed as plasma levels of ADMA and L-arginine.

Methods

A male population (n = 563, age 70 ± 6 yrs) with long-standing hyperlipidemia, characterized as high risk individuals in 1970–72, was included, randomly allocated to receive placebo n-3 PUFA capsules (corn oil) and no dietary advice (control group), dietary advice (Mediterranean type), n-3 PUFA capsules, or dietary advice and n-3 PUFA combined and followed for 3 years. Fasting blood samples were drawn at baseline and the end of the study.

Results

Compliance with both intervention regimens were demonstrated by changes in serum fatty acids and by recordings from a food frequency questionnaire. No influence of either regimens on ADMA levels were obtained. However, n-3 PUFA supplementation was accompanied by a significant increase in L-arginine levels, different from the decrease observed in the placebo group (p < 0.05). In individuals with low body mass index (<26 kg/m²), the decrease in L-arginine on placebo was strengthened (p = 0.01), and the L-arginine/ADMA ratio was also significantly reduced (p = 0.04).

Conclusion

In this rather large randomized intervention study, ADMA levels were not influenced by n-3 PUFA supplementation or dietary counselling. n-3 PUFA did, however, counteract the age-related reduction in L-arginine seen on placebo, especially in lean individuals, which might be discussed as an improvement of endothelial function.

Introduction

Endothelial dysfunction is an early and crucial event in the pathogenesis of atherosclerosis and cardiovascular disease 1. It is reflecting an imbalance between the vasoconstriction and vasodilatation components and is associated with several risk factors such as hypercholesterolemia, hypertension, diabetes and ageing. The vascular endothelium plays an important role in maintenance of vasodilatation through the release of nitric oxide (NO), and central to the development of endothelial dysfunction is reduced bioactive endothelial NO. NO is synthesized from L-arginine by NO-synthase, and the endothelial derived NO is, beyond being an endogenous vasodilator, important in maintenance of cardiovascular homeostasis 2345.

Local administration of L-arginine is known to improve impaired endothelial function in the coronary 6 and also in the forearm 7 vascular beds. Furthermore, oral L-arginine supplementation has been shown to increase the plasma L-arginine levels with subsequent improvement of endothelial function in healthy elderly individuals 8.

Raised plasma levels of asymmetric dimethylarginine (ADMA), an endogenous competitive inhibitor of NO synthase 9, have been shown to antagonize the endothelium-dependent vasodilatation 91011, and increased levels of ADMA have been shown to be associated with increased risk of coronary events in a selected population 12. Several studies support the view that the ratio between L-arginine and ADMA is important for the regulation of endothelial NO-synthase activity 81314.

From epidemiological and clinical studies the importance of certain dietary patterns with regards to cardiovascular disease seems obvious 151617. Especially, dietary fat and fatty acids which affect plasma lipids and lipoproteins and thus are linked to atherosclerosis, are of importance 18. The clinical benefits of omega-3 polyunsaturated fatty acids (n-3 PUFA) of marine origin are well recognized 1920. The exact mechanism by which n-3 PUFAs exert their cardioprotective effect is, however, still not fully understood. In addition to substantial reduction in serum triglyceride level, they have been shown to be antithrombogenic and antiarrhythmic, and also to improve endothelial dysfunction 21222324. An important role of dietary factors in modulating endothelial function by improving endothelium-dependent vasodilatation has also been suggested by mechanisms still unknown 252627.

In the present study we wanted to explore whether n-3 PUFA supplementation and/or diet intervention have beneficial influence on endothelial function assessed as plasma ADMA and L-arginine levels in a male population with long-standing hyperlipidemia. As increased plasma concentrations of ADMA have been reported to be strongly related to components of the metabolic syndrome 28293031, we wanted to investigate the impact of the intervention strategies with special emphasis on insulin resistance and overweight.

Materials and methods

This is a follow-up study of participants from the Oslo Diet and Anti-smoking study carried out 1972–1977 32, comprising 1232 men with hypercholesterolemia (total cholesterol > 6.45 mmol/L, 80% smokers) and at high risk for coronary heart disease. The survivors of this population were 25 years later invited to participate in the Diet and Omega-3 Intervention Trial on Atherosclerosis (DOIT), a 3-year intervention trial aimed to investigate the effect of n-3 PUFA supplementation and/or dietary intervention on markers of atherosclerosis 33. Altogether, a total of 563 subjects, age 64–76 years, were included in the DOIT study. The study was carried out in compliance with the Helsinki Declaration and was approved by the Regional Ethics Committee. All subjects gave their written informed consent to participate.

Study design

This study had a 2 × 2 factorial design, and the participants were randomly assigned to receive n-3 PUFA placebo capsules (corn oil) and no dietary advise (control group), dietary advice and n-3 PUFA placebo capsules, no dietary advise and n-3 PUFA capsules, and finally dietary advice and n-3 PUFA capsules combined. The dietary advice was individually given by a clinical nutritionist based on a food frequency questionnaire 34. Energy content and nutrient composition of the diet were calculated from the questionnaires at baseline and the end of the study (36 months). The dietary advice was given during 0–45 minutes at time of randomization, for 30 minutes after 3 months, and then further every 6 month. Individual optimal diet was worked out in cooperation with the participants and if possible – his wife. The subjects were supported with a margarine rich in polyunsaturated acids (based on sunflower and rapeseed oil) and vegetable oils (rapeseed oil), free of costs. In addition, to decrease use of meat, advices to increase intake of vegetables, fruit and fish, targeting at energy percents from fat 27–30%, protein 15–18% and carbohydrate 50–55% (a "Mediterranean type" diet), were given. The n-3 PUFA capsules (Pikasol^®, Lube, Denmark) used, contained about 60% n-3 PUFA, mainly eicosapentaenoic acid (20:5) and docosahexaenoic acid (22:6) in a ratio 2:1, and 3.4 mg/g tocopherols to avoid peroxidation of the capsules. The placebo capsules (corn oil) contained 56% linoleic acid (18:2 n-6), 32% oleic acid (18:1 n-9), 10% palmitic acid (16:0) and 3.0 mg/g tochopherols. Two capsules twice daily, corresponding to a daily intake of either 2.4 g n-3 PUFA or 2.4 g corn oil, were given.

Insulin resistance was estimated according to a Homeostasis model assessment (HOMA) score, calculated with the following formula: (fasting insulin/7.2)/(22.5/fasting glucose), as described by Matthews and coworkers 35. Subjects were defined as overweight if they had body mass index ≥ 26 kg/m²(median value of the population).

Blood sampling

Venous blood samples were collected in an overnight fasting state at 7:30 to 10 am. EDTA plasma (0.34 M EDTA-K3) was prepared for determination of the dimethylarginines and oxidized low density lipoprotein cholesterol (oxLDL-C), whereas serum was used for nitrate/nitrite, thiobarbituric-acid-reacting substances, insulin, glucose and lipid analyses. Plasma and serum were kept frozen at -70°C for batch analysis, except for the lipid analyses.

Laboratory methods

Total cholesterol, high density lipoprotein cholesterol, triglycerides, creatinine, glucose and HbA1c were determined by conventional methods. Low density lipoprotein cholesterol was calculated according to Friedewald's formula. Serum fatty acid composition was analyzed in a sub-set of participants (n = 278) by gas-liquid chromatography as previously described 3637. Thiobarbituric-acid-reacting substances were determined by a colorimetric method 12. Insulin was analyzed using a competitive radioimmunoassay kit from Linco Research, Inc, St. Charles, MO, USA. This method is based on a sandwich ELISA technique. OxLDL-C was measured with an ELISA kit from Mercodia AB, Uppsala, Sweden. The method is based on a direct sandwich technique in which two monoclonal antibodies are directed against separate antigenic determinants on the oxidized apolipoprotein B molecule. Nitrate/nitrite was analyzed using Total Nitric Oxide Assay kit (R&D System Europe, Abingdon, UK). Briefly, this assay is based on the enzymatic conversion of nitrate to nitrite by nitrate reductase. The reaction is followed by a colorimetric detection (540 nm) of nitrite as an azo dye product of the Griess reaction. To minimize interference with plasma proteins, the samples were ultrafiltrated through a 12 kDa cut-off filter (VectaSpin Micro 12 K MWCO, Whatman International Ltd, Maidstone, England) prior to the analysis of nitrate/nitrite.

Plasma concentration of L-arginine, ADMA and symmetric dimethylarginine (SDMA) were measured by high performance liquid chromatography and precolumn derivatization with o-phthaldialdehyde (Sigma Chemicals Co, St. Louis, MO) as previously described in detail 14. The recoveries of L-arginine, ADMA and SDMA with this method were 84%, 91% and 92%, respectively. Detection limit of the assays were 0,025 μM and the intra- and interassay coefficients of variation, based on pooled plasma samples, were ≤ 5% for all.

Statistics

For demographic variables proportions are given. For the nutrient components, data are presented as mean ± SD and t-test was used for group comparisons. As several biochemical variables were skewly distributed, these data are presented as medians and 25,75 percentiles and non-parametric statistics used. Intra-group changes from baseline to 36 months were evaluated by Wilcoxon test. Between-group differences were evaluated by Mann-Whitney U test or Kruskal-Wallis test. Analyzes were performed mainly according to the factorial design, thus diet intervention was compared to no diet intervention and n-3 PUFA intervention was compared to placebo. The level of statistical significance was set at p < 0.05. The SPSS 11.0 (SPSS INC., Chicago, Illinois, USA) software package was used for statistical analysis.

Results

Of the 563 included participants, 487 completed the 36 months intervention, 40 had died, 27 dropped out due to disease states interfering with study follow up and 9 individuals were unwilling to complete the study period.

Some clinical characteristics and use of medication for the study population at baseline are presented in Table 1. No statistically significant differences between the intervention groups were found.

Table 1

Clinical characteristics, use of medication and fasting lipid variables in the no dietary advice and the dietary advice groups, and in the placebo (corn oil) and the n-3 PUFA supplemented groups. Median values (25, 75 percentiles) or proportions are given.

No Diet Intervention

Diet Intervention

Placebo (corn oil)

n-3 PUFA

279

281

282

Age (yrs)(range)

70 (67, 76)

70 (67, 73)

70 (67, 72)

70 (68, 73)

Verified CVD %

Diabetes %

Hypertension %

Smokers %

Medications: %

Statins

Acetylsalicylic acid

βeta-blockers

ACE-inhibitors

Nitrates

Total Cholesterol (mmol/L)

6.4 (5.8, 7.0)

6.3 (5.5, 6.9)

6.3 (5.6, 6.8)

6.3 (5.7, 7.1)

HDL-C (mmol/L)

1.4 (1.1, 1.6)

1.4 (1.2, 1.6)

LDL-C (mmol/L)

4.1 (3.5, 4.8)

4.0 (3.5, 4.6)

4.1 (3.5, 4.6)

4.1 (3.5, 4.8)

Triglycerides (mmol/L)

1.5 (1.3, 2.1)

1.6 (1.1, 2.0)

1.5 (1.1, 2.0)

1.6 (1.1, 2.1)

CVD: Cardiovascular disease, ACE: Angiotensin converting enzyme, HDL-C: High density lipoprotein cholesterol, LDL-C: Low density lipoprotein cholesterol

Dietary intake, serum n-3 PUFA and serum lipids

The energy and nutrient composition of the participants' habitual diet at baseline and after the study period, obtained from the food frequency questionnaire, are given in Table 2. At baseline, significantly higher levels of polyunsaturated fat and the polyunsaturated/saturated fat ratio were observed in the no dietary advise group compared to the dietary counseling group. At the end of the study no differences in changes were seen between the groups for energy and protein intake, whereas the increase in carbohydrate and the reduction in total fat intake was significantly greater in the dietary counseling group (p < 0.05 for both). Furthermore, the reduction in saturated fat, the increase in α-linolenic acid and the increase in the polyunsaturated/saturated fat ratio in the dietary counseling group, were significantly greater than in the no dietary advise group, indicating compliance to the dietary advice given.

Table 2

Nutrient pattern and some dietary fatty acids (mean ± SD) recorded in the no dietary advice and the dietary advice groups at baseline and after 36 months.

No Diet Intervention

Diet Intervention

Baseline (n = 279)

36 Months (n = 241)

Baseline (n = 279)

36 Months (n = 244)

Energy (MJ)

8.6 ± 2.0

7.8 ± 1.8^c

8.5 ± 2.1

7.7 ± 1.9^c

Carbohydrates (g/d)

247 ± 65

228 ± 61^a

246 ± 71

234 ± 63^c

% of energy

48.6 ± 6.2

50.0 ± 6.4^b

49.1 ± 6.6

51.7 ± 6.8^c

<0.01

Protein (g/d)

82 ± 19

76 ± 17^c

82 ± 19

77 ± 19^c

% of energy

16.3 ± 2.3

16.8 ± 2.4^b

16.6 ± 2.6

17.1 ± 2.5^a

Fat (g/d)

73 ± 22

62 ± 20^c

71 ± 24

58 ± 20^c

% of energy

31.3 ± 5.5

29.6 ± 5.4^c

30.4 ± 5.4

27.6 ± 5.5^c

<0.05

Fatty acids (g/d)

Saturated fat

27.2 ± 9.9

24.2 ± 8.5^c

27.0 ± 10.4

21.4 ± 8.3^c

<0.01

Monounsaturated fat

27.0 ± 8.1

20.1 ± 6.4^c

26.0 ± 8.7

18.4 ± 6.3^c

Polyunsaturated fat*

13.8 ± 5.0

12.7 ± 4.9^c

12.5 ± 5.0

13.1 ± 5.5

<0.001

Omega 6*

10.0 ± 4.1

9.9 ± 4.1

8.9 ± 4.1

9.9 ± 4.7^b

<0.01

Omega 3^†

2.9 ± 1.3

2.5 ± 1.2^c

2.8 ± 1.2

2.7 ± 1.1

<0.01

α-linolenic acid*

1.4 ± 0.6

1.2 ± 0.6

1.4 ± 0.6^c

<0.01

P/S ratio*

0.53 ± 0.17

0.55 ± 0.16

0.49 ± 0.16

0.63 ± 0.17^c

<0.001

MJ: Megajoule, P/S ratio: Polyunsaturated/Saturated fat.

Saturated fatty acids: C14:0, C16:0, C18:0, Omega 6 fatty acids: C18:2, C20:4, Omega 3 fatty acids: C18:3, C20:5, C22:5, C22:6.

* refer to significant intergroup differences at baseline.

^ap < 0.05, ^bp < 0.01, ^cp < 0.001 refer to within group changes from baseline to 36 months.

p refers to differences in changes from baseline to 36 months between the groups, ns = non significant.

^†As subjects were included for trial of n-3 PUFA supplementation, this intake is not expressed in the table.

The serum levels of the selected PUFA's at baseline and after 36 months are presented in Table 3. Significant increases in eicosapentaenoic acid (20:5n-3), docosahexaenoic acid (22:6n-3) and sum n-3 and an improved polyunsaturated/saturated fat ratio were found for subjects receiving n-3 PUFA supplementation compared to subjects on placebo (p < 0.001 for all), indicating good compliance with the intervention. The reductions obtained in linoleic acid (18:2n-6), arachidonic acid (20:4n-6) and sum n-6 were all significantly greater on n-3 PUFA supplementation compared to placebo (p < 0.01 for all). No difference in changes between the groups in alphalinolenic acid (18:3n-3) was found.

Table 3

Levels of some selected serum fatty acids (g/L) at baseline and after 36 months, in the placebo (corn oil) and the n-3 PUFA supplemented groups. Median values (25, 75 percentiles) are given.

placebo (corn oil)

n-3 PUFA

Baseline (n = 139)

36 Months (n = 114)

Baseline (n = 139)

36 Months (n = 122)

Linoleic acid, 18:2n-6

1.59 (1.33, 1.82)

1.58 (1.36, 1.81)

1.70 (1.47, 1.96)

1.47 (1.24, 1.70)^b

<0,001

AA, 20:4n-6

0.23 (0.20, 0.27)

0.25 (0.21, 0.30)^b

0.22 (0.19, 0.27)

0.21 (0.18, 0.25)^b

<0,001

ALA, 18:3n-3

0.030 (0.022, 0. 39)

0.031 (0.024, 0.037)

0.033 (0.026, 0.043)

0.031 (0.025, 0.042)

EPA, 20:5n-3

0.076 (0.049, 0.13)

0.070 (0.041, 0.11)^a

0.081 (0.051, 0.14)

0.22 (0.17, 0.27)^b

<0,001

DHA, 22:6n-3

0.14 (0.12, 0.19)

0.14 (0.11, 0.18)

0.17 (0.12, 0.20)

0.20 (0.16, 0.23)^b

<0,001

Sum n-6

1.82 (1.57, 2.11)

1.86 (1.58, 2.06)

1.94 (1.68, 2.22)

1.68 (1.44, 1.94)^b

<0,001

Sum n-3

0.27 (0.20, 0.38)

0.26 (0.21, 0.35)

0.31 (0.22, 0.41)

0.49 (0.39, 0.57)^b

<0,001

Ratio omega-6/omega-3

6.85 (4.75, 9.27)

7.08 (5.35, 9.44)

6.36 (4.70, 8.37)

3.40 (2.69, 4.28)^b

<0,001

Total fatty acids in serum

5.31 (4.58, 6.22)

5.04 (4.40, 5.70)

5.29 (4.60, 6.25)

4.73 (4.05, 5.59)^b

0.011

AA: Arachidonic acid, ALA: Alphalinolenic acid, EPA: Eicosapentaenoic acid, DHA: Docosahexaenoic acid.

^ap < 0.05, ^bp < 0.01 refer to within group changes from baseline to 36 months

p: refers to differences in changes from baseline to 36 months between the group

The triglycerides were significantly more reduced in the dietary advice group as compared to the no dietary advice group (from 1.6 to 1.2 mmol/L vs 1.5 to 1.3 mmol/L, p < 0.01). After the n-3 PUFA intervention, total cholesterol and triglycerides were both significantly reduced when compared to placebo (from 6.3 to 6.2 mmol/L vs 6.3 to 6.3 mmol/L, p < 0.05, and from 1.6 to 1.1 mmol/L vs 1.5 to 1.4 mmol/L, p < 0.01, respectively). Otherwise no changes were obtained.

Carbohydrates and markers of peroxidation

Glucose, insulin and the HOMA score were significantly reduced, whereas HbA1c was increased at the end of the study in all groups, but no differences in changes between any intervention groups were found. No effects of either intervention strategies were furthermore observed for thiobarbituric-acid-reacting substances, oxLDL-C and nitrate/nitrite (Table 4).

Table 4

Dimethylarginines and some associated variables, markers of peroxidation and carbohydrates at baseline and after 36 months according to the intervention strategies. Median values (25, 75 percentiles) are given.

No Diet Intervention

Diet Intervention

Placebo (corn oil)

n-3 PUFA

Baseline (n = 279)

36 Months (n = 241)

Baseline (n = 279)

36 Months (n = 244)

Baseline (n = 281)

36 Months (n = 239)

Baseline (n = 282)

36 Months (n = 248)

ADMA (μM)

1.42 (1.11, 1.75)

1.41 (1.14, 1.78)

1.38 (1.15, 1.76)

1.40 (1.12, 1.77)

1.38 (1.10, 1.77)

1.39 (1.14, 1.80)

1.39 (1.16, 1.75)

1.42 (1.13, 1.76)

0.62

0.93

SDMA (μM)

0.23 (0.17, 0.33)

0.26 (0.17, 0.38)*

0.23 (0.16, 0.34)

0.26 (0.17, 0.39)

0.22 (0.16, 0.33)

0.26 (0.18, 0.38)

0.23 (0.17, 0.34)

0.26 (0.17, 0.39)

0.24

0.71

L-arginine (μM)

85 (76, 97)

85 (76, 94)

86 (76, 98)

86 (75, 99)

87 (76, 97)

84 (75, 95) ^†

85 (77, 97)

88 (76, 97)

0.80

<0.05

L-arg/ADMA

62 (48, 76)

59 (47, 77)

61 (49, 78)

61 (49, 80)

62 (49, 78)

60 (47, 77)

62 (48, 77)

61 (49, 80)

0.97

0.32

Nitrate/nitrite (μM)

26.2 (22.0, 34.4)

27.6 (21.7, 34.3)

25.9 (21.5, 35.2)

26.4 (21.7, 34.4)

25.5 (21.6, 36.1)

27.3 (21.5, 34.8)

27.4 (21.9, 34.3)

27.1 (21.9, 34.2)

0.99

0.65

oxLDL-C (U/L)

68 (57, 80)

61 (47, 74) ^‡

65 (53, 84)

59 (48, 75) ^‡

65 (54, 82)

60 (47, 74) ^‡

69 (55, 82)

60 (49, 74) ^‡

0.49

0.25

TBARS (μmol/L)

1.20 (0.96, 1.68)

1.28 (0.96, 1.76)

1.20 (0.96, 1.60)

1.20 (0.88, 1.60)

1.20 (0.96, 1.60)

1.28 (0.96, 1.68)

1.20 (0.96, 1.68)

1.20 (0.88, 1.68)

0.75

0.73

Glucose (mmol/L)

5.6 (5.3, 6.3)

5.5 (5.0, 6.1) ^†

5.6 (5.3, 6.2)

5.4 (5.0, 5.9) ^‡

5.6 (5.3, 6.3)

5.5 (5.0, 6.1) ^‡

5.6 (5.2, 6.1)

5.5 (5.0, 6.0) ^‡

0.08

0.75

HbA1c (%)

5.6 (5.3, 5.9)

5.7 (5.5, 6.1) ^‡

5.6 (5.3, 5.8)

5.7 (5.5, 5.9) ^‡

5.6 (5.4, 5.9)

5.7 (5.5, 6.1) ^‡

5.5 (5.3, 5.8)

5.7 (5.5, 5.9) ^‡

0.41

0.31

Insulin (pmol/L)

112 (92, 153)

109 (85, 139) ^‡

121 (94, 154)

105 (83, 131) ^‡

120 (94, 155)

109 (87, 143) ^‡

113 (92, 152)

103 (79, 131) ^‡

0.28

0.35

HOMA score

4.0 (3.0, 5.7)

3.7 (2.8, 5.0) ^‡

4.3 (3.2, 5.5)

3.6 (2.7, 4.7) ^‡

4.3 (3.3, 5.8)

3.7 (2.9, 5.3) ^‡

4.0 (3.0, 5.6)

3.5 (2.7, 4.6) ^‡

0.16

0.40

Creatinine (μmol/L)

88 (80, 96)

96 (89, 109) ^‡

88 (81, 99)

97 (89, 109) ^‡

88 (80, 96)

96 (87, 106) ^‡

88 (81, 98)

97 (89, 110) ^‡

<0.05

0.21

BMI (kg/m²)

26.5 (24.3, 28.7)

26.6 (24.6, 29.3)

26.5 (24.0, 28.5)

26.2 (23.8, 28.7)

26.6 (23.9, 28.8)

26.8 (24.3, 29.3)

26.4 (24.2, 28.4)

26.3 (24.3, 28.4)

<0.05

0.071

SBP (mmHg)

149 (134, 160)

143 (132, 156) ^‡

147 (137, 161)

142 (128, 154) ^‡

148 (134, 161)

142 (129, 156) ^‡

148 (138, 160)

142 (131, 154) ^‡

0.40

0.48

DBP (mmHg)

83 (76, 91)

79 (72, 87) ^‡

84 (77, 91)

78 (70, 86) ^‡

84 (77, 91)

78 (70, 87) ^‡

84 (77, 91)

78 (71, 86) ^‡

0.09

0.40

TBARS: thiobarbituric-acid-reacting substances, BMI: Body mass index, SBP: systolic blood pressure, DBP: diastolic blood pressure.

* p <0.05, ^†p <0.01, ^‡p <0.001, refers to intra group changes from baseline to 36 months.

p1 and p2, refers to differences in changes from baseline to 36 months between diet and no-diet intervention, and PUFA and placebo supplementation, respectively.

Dimethylarginines

There were no group differences in the levels of ADMA, L-arginine, the L-arginine/ADMA ratio or SDMA at baseline (Table 4). There were also no differences in these variables in subjects treated with statins, angiotensin converting enzyme inhibitors, β-blockers or nitrates, when compared with untreated individuals at baseline.

At the end of the study, no changes in the dimethylarginines or L-arginine were observed in the dietary advice group as compared to the no dietary advice group.

In the n-3 PUFA supplementation group no changes in the levels of dimethylarginines were found. However, a significant reduction in L-arginine levels was observed in the placebo group (p < 0.01), significantly different from the increase in the n-3 PUFA group (p < 0.05). Analyzed by single group comparisons, borderline significant increased levels of L-arginine were found in the n-3 PUFA treatment group alone as compared to control (p = 0.065).

Analyzed separately according to being overweight or not, in subjects with low body mass index (< 26 kg/m²) the reduction in L-arginine levels on placebo compared to n-3 PUFA supplementation, was more pronounced (p = 0.01) and the L-arginine/ADMA ratio was significantly more reduced (p = 0.040) (Figure 1). No differences between the intervention groups were recorded in these variables at baseline in this respect.

Figure 1

L-arginine and L-arginine/ADMA ratio at baseline and after 36 months in subjects with A) high body mass index (>26 kg/m²) and B) low body mass index (<26 kg/m²) on placebo (corn oil) (n = 101) or n-3 PUFA supplementation (n = 110). Median values are given. p-values refer to differences in changes from baseline to 36 months between the groups.

Analyzed according to quartiles of the HOMA score no effects of the interventions strategies were recorded at any level of insulin resistance.

Discussion

The present study was undertaken to explore whether long-term n-3 PUFA supplementation and/or dietary intervention had beneficial influence on plasma levels of ADMA and L-arginine/ADMA ratio, thus an improvement of endothelial function.

In response to n-3 PUFA supplementation, an increase in plasma L-arginine levels was observed, in contrast to the decrease seen in the placebo group, most pronounced in individuals not overweighed. No effects of dietary changes towards a Mediterranean type diet on these variables were found in this population of elderly high risk men. Satisfactory compliance with both regimens was demonstrated by changes in nutrient pattern and in the changes in the serum fatty acid profile.

To our knowledge this is the first report on which effects of n-3 PUFA supplementation and/or dietary counseling on the levels of L-arginine and dimethylarginines have been evaluated. It has previously been focused on a potential role of n-3 PUFA in modulating vascular contraction and vasodilatation 383940. Increased endogenous NO production following supplementation with fish oil has been reported 41, which may be responsible for the improvement in endothelial function observed with n-3 PUFA 2123. Our hypothesis was that this might be through an effect on ADMA levels, accompanied by an increased production of NO. However, the improvement may rather be through increased L-arginine levels as demonstrated in the present study. Previous studies have shown that administration of L-arginine has improved impaired endothelial function and inhibited the progression of atherosclerosis in humans, especially in healthy elderly individuals, as well as in experimental animal studies 26813. In line with our observations with n-3 PUFA, Bode-Boger et al. demonstrated that dietary L-arginine supplementation elevated the L-arginine/ADMA ratio by increasing plasma L-arginine levels, while the concentrations of ADMA were unaffected, through mechanisms not known. Previous studies using different intervention principles known to improve endothelial dysfunction, have revealed that to influence ADMA levels directly are difficult 21442. Why the beneficial effect of n-3 PUFA on L-arginine and subsequently on the L-arginine/ADMA ratio was strengthened in normal (non-overweight) individuals is not easily explainable. We have previously demonstrated that overweight and insulin resistant individuals have elevated levels of ADMA and reduced L-arginine/ADMA ratio 31, and our hypothesis was that these subjects would benefit more from the intervention strategies.

Several studies have reported correlation between ADMA and serum lipid variables 13144344. Despite the reduction in intake of dietary fat and triglycerides after long term dietary intervention and in triglycerides and total cholesterol after n-3 PUFA supplementation, this was not accompanied by reduction in ADMA levels or increased nitrate/nitrite concentrations in our study.

The so called Mediterranean diet has previously been reported to be favorable regarding recurrence of myocardial infarction in the LYON Heart Study 1645, and for delaying all cause of death after a heart attack in the GISSI study 46. The exact mechanism for the reduced risk for cardiovascular disease after dietary changes towards the Mediterranean diet is not known. Fard et al. have recently demonstrated acute elevation of ADMA levels and impaired endothelial function in response to high-fat meal in patients with type 2 diabetes 11. They proposed that the increase in ADMA levels resulted from a reduction in the expression or enzyme activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme selectively responsible for degradation of ADMA 47. Down regulation of DDAH has also been associated with oxidative stress 2948, which, however was not affected in our study when measured as peroxidation markers. In accordance with our results, Amgring et al. did not find any beneficial effects either on oxidative stress evaluation or in plasma concentrations of insulin and glucose in their short-term diet intervention study of healthy subjects 49. The lack of effect of diet in our study might also be due to the fact that there was a tendency towards improved diet also in the group receiving no dietary advice.

Recently, elevated ADMA concentrations have been linked to metabolic variables related to cardiovascular risk factors like glucose, insulin and insulin resistance 14303150, and glucose per se has been shown important in the regulation of DDAH and ADMA 29. Lack of effects of both intervention principles on these variables may, therefore, explain why ADMA levels were not affected in the present study.

The modest effects found in our study may be explained by the heterogeneity of this older population, survivors from a population at high risk for cardiovascular disease, using a broad spectrum of medication that may affect the levels of ADMA and L-arginine through mechanisms not known, although no influence of the recorded medications could be seen. However, the present study confirms that the study subjects at baseline had ADMA levels similar to what have been shown in subjects with hypercholesterolemia, with almost 2-fold higher levels than in young healthy subjects 14. This may have pathophysiological significance, as they are within the range shown to inhibit the activity of NO-synthase 515253.

In conclusion, the increased levels of L-arginine observed after long-term n-3 PUFA supplementation, counteracting the age related decrease seen in the placebo group, especially in lean individuals, might be discussed as an improvement of endothelial function. Neither long-term n-3 PUFA supplementation nor dietary counseling towards a Mediterranean type diet had effect on the levels of ADMA in our population of elderly high risk men.

Acknowledgements

Paula Berstad and Hanne S. Kleven are greatly acknowledged for laboratory assistance.

The study was supported by the Norwegian Council for Cardiovascular Diseases, The Norwegian Retail Company RIMI and Ada og Hagbart Waages Humanitære Stiftelse. We thank Mills DA for supplying margarine and vegetable oils.

The pathogenesis of atherosclerosis: a perspective for the 1990s Ross R Nature 1993 362 6423 801 809 10.1038/362801a0 8479518 Dietary L-arginine reduces the progression of atherosclerosis in cholesterol-fed rabbits: comparison with lovastatin Boger RH Bode-Boger SM Brandes RP Phivthong-ngam L Bohme M Nafe R Circulation 1997 96 4 1282 1290 9286960 Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells Garg UC Hassid A J Clin Invest 1989 83 5 1774 1777 303890 2540223 Nitric oxide: an endogenous modulator of leukocyte adhesion Kubes P Suzuki M Granger DN Proc Natl Acad Sci U S A 1991 88 11 4651 4655 51723 1675786 10.1073/pnas.88.11.4651 Dietary L-arginine supplementation normalizes platelet aggregation in hypercholesterolemic humans Wolf A Zalpour C Theilmeier G Wang BY Ma A Anderson B J Am Coll Cardiol 1997 29 3 479 485 10.1016/S0735-1097(97)00523-8 9060881 Aging-associated endothelial dysfunction in humans is reversed by L-arginine Chauhan A More RS Mullins PA Taylor G Petch C Schofield PM J Am Coll Cardiol 1996 28 7 1796 1804 10.1016/S0735-1097(96)00394-4 8962569 Hypertension causes premaure aging of endothelial function in humans Taddei S Virdis A Mattei P Hypertension 1997 29 736 43 9052889 Oral L-arginine improves endothelial function in healthy individuals older than 70 years Bode-Boger SM Muke J Surdacki A Brabant G Boger RH Frolich JC Vascular Medicine 2003 8 2 77 81 10.1191/1358863x03vm474oa 14518608 Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure Vallance P Leone A Calver A Collier J Moncada S Lancet 1992 339 8793 572 575 10.1016/0140-6736(92)90865-Z 1347093 Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia Boger RH Bode-Boger SM Szuba A Tsao PS Chan JR Tangphao O Circulation 1998 98 18 1842 1847 9799202 Acute elevations of plasma asymmetric dimethylarginine and impaired endothelial function in response to a high-fat meal in patients with type 2 diabetes Fard A Tuck CH Donis JA Sciacca R Di Tullio MR Wu HD Arteriosclerosis, Thrombosis & Vascular Biology 2000 20 9 2039 2044 Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine Valkonen VP Paiva H Salonen JT Lakka TA Lehtimaki T Laakso J Lancet 2001 358 9299 2127 2128 10.1016/S0140-6736(01)07184-7 11784629 Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits Bode-Boger SM Boger RH Kienke S Junker W Frolich JC Biochem Biophys Res Commun 1996 219 2 598 603 10.1006/bbrc.1996.0279 8605033 Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin Eid HM Eritsland J Larsen J Arnesen H Seljeflot I Atherosclerosis 2003 166 2 279 284 10.1016/S0021-9150(02)00206-X 12535740 Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART) Burr ML Fehily AM Gilbert JF Rogers S Holliday RM Sweetnam PM Lancet 1989 2 8666 757 761 10.1016/S0140-6736(89)90828-3 2571009 Mediterranean alpha-linolenic acid-rich diet in secondary prevention of coronary heart disease de Lorgeril M Renaud S Mamelle N Salen P Martin JL Monjaud I Lancet 1994 343 8911 1454 1459 10.1016/S0140-6736(94)92580-1 7911176 Fish consumption and coronary heart disease mortality. A systematic review of prospective cohort studies Marckmann P Gronbaek M Eur J Clin Nutr 1999 53 8 585 590 10.1038/sj.ejcn.1600832 10477243 Diet and helath, in HUI YH: Bailey's Industrial Oil and Fat Products Watkins BA Henning B Toborek M Edible Oil and Fat Products: General Apllications 1996 1 159 214 Effect of dietary supplementation with n-3 fatty acids on coronary artery bypass graft patency Eritsland J Arnesen H Gronseth K Fjeld NB Abdelnoor M Am J Cardiol 1996 77 1 31 36 10.1016/S0002-9149(97)89130-8 8540453 Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico Lancet 1999 354 9177 447 455 10.1016/S0140-6736(99)07072-5 10465168 Dietary supplementation with marine omega-3 fatty acids improve systemic large artery endothelial function in subjects with hypercholesterolemia Goodfellow J Bellamy MF Ramsey MW Jones CJ Lewis MJ J Am Coll Cardiol 2000 35 2 265 270 10.1016/S0735-1097(99)00548-3 10676668 Fish oils and plasma lipid and lipoprotein metabolism in humans: a critical review Harris WS J Lipid Res 1989 30 6 785 807 2677200 Fish oil and cardiovascular disease: lipids and arterial function Nestel PJ Am J Clin Nutr 2000 71 1 Suppl 228S 231S 10617976 Effects of dietary fish oil on ventricular premature complexes Sellmayer A Witzgall H Lorenz RL Weber PC Am J Cardiol 1995 76 12 974 977 10.1016/S0002-9149(99)80276-8 7484845 Longchain n-3 polyunsaturated fatty acids and blood vessel function Abeywardena MY Head RJ Cardiovasc Res 2001 52 3 361 371 10.1016/S0008-6363(01)00406-0 11738053 Mediterranean and low-fat diets improve endothelial function in hypercholesterolemic men Fuentes F Lopez-Miranda J Sanchez E Sanchez F Paez J Paz-Rojas E Ann Intern Med 2001 134 12 1115 1119 11412051 Vascular effects of step I diet in hypercholesterolemic patients with coronary artery disease Koh KK Ahn JY Choi YM Han SH Kim DS Kim HS Am J Cardiol 2003 92 6 708 710 10.1016/S0002-9149(03)00832-4 12972113 Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus Abbasi F Asagmi T Cooke JP Lamendola C McLaughlin T Reaven GM Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase Lin KY Ito A Asagami T Tsao PS Adimoolam S Kimoto M Circulation 2002 106 8 987 992 10.1161/01.CIR.0000027109.14149.67 12186805 Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor Stuhlinger MC Abbasi F Chu JW Lamendola C McLaughlin TL Cooke JP JAMA 2002 287 11 1420 1426 10.1001/jama.287.11.1420 11903029 Relationship between obesity, smoking and the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine (ADMA) Eid HMA Arnesen H Hjerkinn EM Lyberg T Seljeflot I Metabolism 2004 53 1574 9 10.1016/j.metabol.2004.06.026 15562402 Effect of diet and smoking intervention on the incidence of coronary heart disease. Report from the Oslo Study Group of a randomised trial in healthy men Hjermann I Velve BK Holme I Leren P Lancet 1981 2 8259 1303 1310 10.1016/S0140-6736(81)91338-6 6118715 The influence of long-term intervention with dietary counselling, long chain n-3 fatty acids supplements or both on circulating markers of endothelial activiation in men with long-standing hyperlipidemia Hjerkinn EM Seljeflot I Ellingsen I Berstad P Hjermann I Sandvik L Arnesen H Am J Clin Nutr 2005 81 583 9 15755826 Evaluation of a food frequency questionnaire with weighed records, fatty acids, and alpha-tocopherol in adipose tissue and serum Andersen LF Solvoll K Johansson LR Salminen I Aro A Drevon CA Am J Epidemiol 1999 150 1 75 87 10400557 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man Matthews DR Hosker JP Rudenski AS Naylor BA Treacher DF Turner RC Diabetologia 1985 28 7 412 419 10.1007/BF00280883 3899825 A simple method for the isolation and purification of total lipides from animal tissues Folch J Lees M Sloane Stanley GH J Biol Chem 1957 226 1 497 509 13428781 Esterification of fatty acids at room temperature by chloroform-methanolic HCl-cupric acetate Hoshi M Williams M Kishimoto Y J Lipid Res 1973 14 5 599 601 4729977 n-3 polyunsaturated fatty acids and the cardiovascular system Angerer P von Schacky C Curr Opin Clin Nutr Metab Care 2000 3 6 439 445 10.1097/00075197-200011000-00005 11085829 Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction Christensen JH Korup E Aaroe J Toft E Moller J Rasmussen K Am J Cardiol 1997 79 12 1670 1673 10.1016/S0002-9149(97)00220-8 9202361 Long-chain omega 3 fatty acids, blood lipids and cardiovascular risk reduction Mori TA Beilin LJ Curr Opin Lipidol 2001 12 1 11 17 10.1097/00041433-200102000-00003 11176197 n-3 fatty acids and urinary excretion of nitric oxide metabolites in humans Harris WS Rambjor GS Windsor SL Diederich D Am J Clin Nutr 1997 65 2 459 464 9022531 Effect of high-dose statin treatment on plasma concentrations of endogenous nitric oxide synthase inhibitors Paiva H Laakso J Lehtimaki T Isomustajarvi M Ruokonen I Laaksonen R J Cardiovasc Pharmacol 2003 41 2 219 222 10.1097/00005344-200302000-00010 12548082 Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine Lundman P Eriksson MJ Stuhlinger M Cooke JP Hamsten A Tornvall P J Am Coll Cardiol 2001 38 1 111 116 10.1016/S0735-1097(01)01318-3 11451259 Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis Miyazaki H Matsuoka H Cooke JP Usui M Ueda S Okuda S Circulation 1999 99 9 1141 1146 10069780 Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study de Lorgeril M Salen P Martin JL Monjaud I Delaye J Mamelle N Circulation 1999 99 6 779 785 9989963 Mediterranean diet and all-causes mortality after myocardial infarction: results from the GISSI-Prevenzione trial Barzi F Woodward M Marfisi RM Tavazzi L Valagussa F Marchioli R Eur J Clin Nutr 2003 57 4 604 611 10.1038/sj.ejcn.1601575 12700623 Does ADMA cause endothelial dysfunction? Cooke JP Arteriosclerosis, Thrombosis & Vascular Biology 2000 20 9 2032 2037 The emerging role of asymmetric dimethylarginine as a novel cardiovascular risk factor Boger RH Cardiovasc Res 2003 59 4 824 833 10.1016/S0008-6363(03)00500-5 14553822 Effects of a Mediterranean-inspired diet on blood lipids, vascular function and oxidative stress in healthy subjects Ambring A Friberg P Axelsen M Laffrenzen M Taskinen MR Basu S Clin Sci (Lond) 2004 106 5 519 525 14683522 Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Chan NN Chan JC Diabetologia 2002 45 12 1609 1616 10.1007/s00125-002-0975-6 12488950 Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease Kielstein JT Boger RH Bode-Boger SM Schaffer J Barbey M Koch KM J Am Soc Nephrol 1999 10 3 594 600 10073610 Effects of an endogenous inhibitor of nitric oxide synthesis on postcapillary venules Kurose I Wolf R Grisham MB Granger DN Am J Physiol 1995 268 6 Pt 2 H2224 H2231 7541959 Studies on the catabolism of Ng-methylarginine, Ng, Ng-dimethylarginine and Ng, Ng-dimethylarginine in the rabbit McDermott JR Biochem J 1976 154 1 179 184 1172690 1275907